醋酸戈舍瑞林缓释植入剂联合比卡鲁胺片治疗晚期老年前列腺癌患者的疗效及临床意义  

Efficacy and significance of goserelin acetate sustained-release implant combined with bicalutamide tablets in advanced senile prostate cancer patients

作　　者：彭浩[1] 李浩[1] 李健[1] PENG Hao;LI Hao;LI Jian(Department of Urology,Zhoukou Central Hospital,Zhoukou 466000,He’nan,China)

机构地区：[1]周口市中心医院泌尿外科

出　　处：《癌症进展》2019年第15期1828-1831,共4页Oncology Progress

摘　　要：目的探讨醋酸戈舍瑞林缓释植入剂联合比卡鲁胺片治疗晚期老年前列腺癌(PCA)患者的临床疗效及对患者生活质量、血清前列腺特异性抗原(PSA)、血管内皮生长因子(VEGF)的影响。方法按照随机数字表法将80例晚期PCA患者分为研究组和对照组,每组40例。对照组患者采用手术去势治疗,研究组患者采用药物去势治疗,即非类固醇抗雄激素药物(醋酸戈舍瑞林缓释植入剂)联合抗雄激素药物(比卡鲁胺)行最大雄激素阻断(MAB)治疗。观察并比较两组患者的临床疗效、生活质量、血清PSA水平、血清VGEF水平,比较两组患者治疗后不良反应发生情况和治疗后1年的生存情况。结果研究组患者的临床总有效率高于对照组患者(P﹤0.05)。治疗后6个月、12个月,两组患者的血清PSA、VEGF水平均低于本组治疗前,且研究组患者的血清PSA、VEGF水平均低于对照组患者(P﹤0.05)。治疗后6个月,研究组和对照组患者的身体情况和生活状况评分均高于本组治疗前,且研究组患者的身体情况和生活状况评分均高于对照组患者(P﹤0.05),但两组患者的社会/家庭状况、与医师的关系、感情状况、前列腺癌特异性生活质量比较,差异均无统计学意义(P﹥0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05)。Log-rank检验结果显示,研究组患者治疗后1年的生存情况优于对照组(P﹤0.05)。结论醋酸戈舍瑞林缓释植入剂联合比卡鲁胺片治疗晚期老年PCA患者的疗效确切,能够有效控制患者的血清PSA和VEGF水平,缓解患者的临床症状,提高患者的生活质量和生存率,且不增加不良反应,值得临床推广应用。Objective To explore the clinical efficacy of goserelin acetate sustained-release implant combined with bicalumide tablets in advanced senile prostate cancer(PCA)patients and its effect on the quality of life,serum prostate specific antigen(PSA)and vascular endothelial growth factor(VEGF)of patients.Method 80 cases of advanced senile PCA patients were selected and divided into research group and control group(40 cases in each group)according to the law of random numbers.The patients in control group were treated with surgieal castration,and the patients in research group were treated with maximum androgen blockage(MAB)i.e.non-steroidal anti-androgen drug(goserelin acetate sustained-release implant)combined with anti-androgen drug(bikalutamide).The clinical efficacy,quality of life,serum PSA,VGEF,post-treatment adverse reaction and 1 year survival rate of the two groups were observed and compared.Result The total effective rate of the research group was significantly higher than that of the control group(P<0.05).The serum PSA,VEGF after 6 months and 12 months treatment were lower than those before treatment,with levels in research group lower than those in control group(P<0.05).Six months after treatment,physical condition and living scores of patientsin both groups were significantly higher than conrresponding scores before treatment,and the scores in research group were higher than those in control group(P<0.05).However,there were no statistically significant differences in the social and family status,relationship with physicians,emotional status and prostate cancer specific quality of life between the two groups(P>0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Log-rank test showed the survival rate in research group was higher than that in control group(P<0.05).Conclusion Goserelin acetate sustained-release implant combined with bicalumide tablets is effective in treating advanced senile PCA,can significantly improve serum PSA

关 键 词：醋酸戈舍瑞林缓释植入剂 比卡鲁胺片 前列腺癌 生活质量 不良反应 

分 类 号：R737.11[医药卫生—肿瘤]